Use of hydroxychloroquin for Covid-19 treatment banned by France govt

The decision came a day after French health organisations, namely, the HCSP health advisory and ANSM drugs agency, advised against using hydroxychloroquine for Covid-19 treatment

France bans hydroxychloroquine as treatment for Covid-19 after studies
According to the study published in the British medical journal, The Lancet, the drug increases the risk of death among the ill and worsens other symptoms
ANI
2 min read Last Updated : May 28 2020 | 8:34 AM IST
France on Wednesday (local time) officially banned hydroxychloroquine as a treatment for Covid-19 after a series of medical studies revealed that the malaria drug could be harmful.

The decision came a day after French health organisations, namely, the HCSP health advisory and ANSM drugs agency, advised against using hydroxychloroquine for Covid-19 treatment, considering its negative side effects.

Moreover, the agency announced that like the World Health Organisation (WHO) did on Monday, it would also pause clinical trials with the drug amid safety measures.

"...This drug (hydroxychloroquine) should not be prescribed to patients with Covid-19," a statement published by the French Health Ministry said.


The French authorities allowed the use of hydroxychloroquine, also prescribed against malaria, in hospitals for Covid-19 patients at the end of March, as there has been no vaccine or any other approved treatment against the disease.

However, according to the study published in the British medical journal, The Lancet, the drug increases the risk of death among the ill and worsens other symptoms, as other studies have concluded.

Notably, the drug has its supporters. Particularly, US President Donald Trump and Brazilian President Jair Bolsonaro have promoted the use of hydroxychloroquine as a treatment for coronavirus.

As of Wednesday, France has reported 182,847 Covid-19 cases, the world's seventh-highest total, with 28,533 related fatalities.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusHydroxychloroquineFrance

Next Story